Neoantigen peptide synthesis service for precision therapeutic discovery

Neoantigens are novel mutated peptides only present within tumour cells. In comparison to conventional immunotherapies, neoantigen-based immunotherapy promotes more potent anti-tumour immune responses with less adversity and off-target consequences. Neoantigen peptides are essential for in vitro functionality screening, pre-clinical trial analysis, and post-clinical efficacy screening when developing personalized cancer vaccines (PCVs) or allogeneic/autologous T-cell treatments (ATCT). However, because of their severe hydrophobicity and other physiochemical characteristics, it is very difficult to manufacture neoantigen peptides. GenScript collaborated with many T-cell therapy and personalized cancer vaccine companies to build the necessary infrastructure for its neoantigen peptide synthesis platform in order to successfully create challenging neoantigen peptides.

In this webinar, you will learn about the applications of neoantigen peptide, and the solution for neoantigen production, through GenScript’s proprietary technologies, for precision immunotherapy development.

Webinar Details

  • Date: December 7th , 2022
  • Time: 2PM SGT
  • Speaker:
Dr. Bon-Kyoung Koo Dr. Gracie Chia, Field

Application Scientist, GenScript

Dr. Gracie Chia is a field application scientist in GenScript Asia Pacific. She completed her PhD degree from Tokyo Institute of Technology, Japan. She has five years of research experience in chemical biology and peptide engineering. Her previous research focuses on establishing functional biomaterials utilizing self-assembling peptide materials for 3D cancer cell culture and drug testing. Upon joining GenScript-APAC, Dr. Chia supports peptide synthesis platform services as the field application scientist. She provides technical support to the commercial team on pre-and post-sale activities.

Related Products

Neoantigen Peptide Synthesis Service

GenScript’s Neoantigen Peptide Synthesis Service can be used for everything from functional screening of neoantigen candidates for TCR therapy to clinical stage vaccine immunogenicity testing.

Stages of Neoantigen Precision Immunotherapy

Speaker-related Webinars

Do you like the current new website?